+

WO2006136449A1 - Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme - Google Patents

Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme Download PDF

Info

Publication number
WO2006136449A1
WO2006136449A1 PCT/EP2006/006094 EP2006006094W WO2006136449A1 WO 2006136449 A1 WO2006136449 A1 WO 2006136449A1 EP 2006006094 W EP2006006094 W EP 2006006094W WO 2006136449 A1 WO2006136449 A1 WO 2006136449A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
treatment
data
previous
medical treatment
Prior art date
Application number
PCT/EP2006/006094
Other languages
English (en)
Inventor
Franck Marchand
Nicolas Roux
Patrick Rambaud
Original Assignee
Ippm Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0506484A external-priority patent/FR2887663A1/fr
Application filed by Ippm Holding Sa filed Critical Ippm Holding Sa
Priority to EP06754539A priority Critical patent/EP1946231A1/fr
Publication of WO2006136449A1 publication Critical patent/WO2006136449A1/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training

Definitions

  • the present invention relates to a method for generating data for 5 optimizing a medical treatment. It also relates to an information system for generating optimizing data, using the method according to the invention, and computing equipment in which this method ' is implemented.
  • This invention is more particularly aimed at a method for correlating pharmacogenetic, pharmacological and medical data, in order to determine 0 the best treatment for a patient.
  • the field of the invention is the medical field.
  • doctors seek to avoid drugs which can produce undesirable reactions. These undesirable reactions can be interactions between drugs in the case where the medical treatment comprises several drugs or reactions 5 caused by the drug on the patient directly.
  • these undesirable reactions can be interactions between drugs in the case where the medical treatment comprises several drugs or reactions 5 caused by the drug on the patient directly.
  • the latter type of reactions there may be mentioned, for example, the allergy that a living organism can have to a drug.
  • the effectiveness of a drug changes depending on the people who use it. Thus, scientists estimate that 90% of drugs only work in 30 to 50% of the population. It is therefore 0 important to consider an individual's response to a treatment before the treatment is administered to him. Otherwise the effectiveness of the treatment can be compromised.
  • a patient's medical history can necessitate a very intense medical treatment.
  • 5 doctors can establish an effective treatment with several drugs. But these drugs can themselves interact. The greater the number of drugs, the greater the chances of interactions between the drugs. It is therefore, in practice, very difficult to find the best medical treatment having no, or the least possible, interaction between drugs. This problem of finding the best 0 possible medical treatment manifests itself in the United States as the fourth cause of mortality according to the studies carried out by the "Centre for Disease Control Fastats".
  • pharmacogenetic knowledge base By pharmacogenetic knowledge base, is understood a base where a set of medical, genetic and pharmaceutical information is stored. Amongst this information, a description of drugs can be found which seeks to constitute the most comprehensive characterization possible of these drugs, of their working and of their undesirable effects, and all the medical data relating to these drugs which are contained in the scientific bases. Therefore, an objective of the invention is to p r opose a combined and comprehensive study of the pharmacogenetic (pharmacogenomic) drug and gene-drug interactions in order to guide the doctor in his therapeutic choices in order to find the best treatment corresponding to each genetically tested patient.
  • the invention proposes a method for generating data for optimizing a medical treatment, implemented in computer equipment, comprising the following stages:
  • the invention is particularly useful as it allows the establishment of a personalized and comprehensive medical treatment for each patient taking account of a great number of pharmacogenetic (pharmacogenomic) interactions including the drug and gene-drug interactions in a manner so as to avoid all interactions, whether they be the product of the drugs or the product of the genetic behaviour of the patient to the drugs or also a combination of reactions which are the product both of the drugs or of the genetic behaviour.
  • pharmacogenetic pharmacogenomic
  • the method according to the invention advantageously allows the doctor to be guided right through the process of deciding the composition of the final medical treatment from the envisaged medical treatment by helping him throughout the decision making process and in the choices to be made.
  • the method according to the invention advantageously allows inclusion of the data contained in the scientific literature and the results of the scientific and genetic testing by means of the pharmacogenetic knowledge base, so as to have the most comprehensive information base possible in order to detect the potential interactions during a medical treatment. Thus, a maximum number of interactions can be detected for maximum optimization.
  • the method according to the invention advantageously allows confirmation of the therapeutic choice.
  • the method can be implemented in order to detect any interactions, but also in order to confirm a choice of medical treatment as being the optimum treatment.
  • the method according to the invention advantageously allows the combination of personal data, such as data on the genotype and on the lifestyle of the patient, with data from the pharmacogenetic knowledge base in order to adapt the optimization of the medical treatment to the patient concerned by the treatment.
  • the method according to the invention proposes, for a medical treatment, a more suitable combination of drugs than that proposed by the doctor or confirmation that the combination of drugs proposed by the doctor is the most suitable.
  • the method according to the invention will try to find the best compromise taking into account several criteria or objectives.
  • One objective would be, for example, to limit the inhibitions on one gene in particular. However it is also necessary to consider that the objectives can interact between each other and minimizing or maximizing one criterion can produce the modification of other factors relating to other objectives.
  • the optimization realized is a evolutionary multicriteria optimization.
  • the objectives of the method according to the invention are the minimizing of certain criteria relating to the medical treatment of a patient.
  • These criteria are associated with functions whose variables are variables from the scientific field, such as the concentration of a product in plasma or the KI of a molecule.
  • the problem of multicriteria optimization can then be expressed as:
  • the latter allows the combination of drugs closest to the compromises found by the multicriteria algorithm to be chosen. It corresponds to the final phase of the process of selecting a suitable treatment.
  • the drugs which are able to be selected are those present in a list of drugs defined previously. These drugs should be documented as regards the quantitative values linked to the input variables of the problem of multicriteria optimization. Otherwise no correlation can be made between an element of the Pareto set and a drug from the list.
  • the data relating to the medical treatment envisaged for the patient can advantageously comprise data on the name and on the intake of the drugs which compose the initial treatment as well as the intake and the duration of the treatment. This advantageously makes it possible to take into account all the data on the medical treatment envisaged and optimization to be carried out on a maximum of points.
  • the data relating to the genotype of the patient can include information on transporters and receptors involved in genetic metabolization of drugs.
  • the data relating to the genotype of the patient can include information on the genes involved in the production of the cytochrome P450 enzymes.
  • the cytochrome P450 plays a significant role in the metabolism of xenobiotics and more than half of the 200 most prescribed drugs in the United States are metabolized by the cytochrome P450 enzymes.
  • genetic studies today mostly relate to the polymorphism of this cytochrome.
  • the information on the genes involved in the production of the cytochrome P450 enzymes states the nature and the combination of alleles of these genes for the patient. It is this information on the nature and the combination of alleles which will lead to the determination of a predictive phenotype for the patient, indicating the attitude of the patient in the metabolization of a drug metabolized by the cytochrome P450 enzymes.
  • the gene-drug interactions taken into account in the method according to the invention, are defined by the phenotype of the patient for the enzyme metabolizing this drug.
  • the cytochrome P450 enzymes which are most often found are the following: CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYPNAT2 and CYP3A4. These enzymes occur either as human isoenzymes of the cytochrome for the metabolization of the drugs, or as enzymes involved in the biotransformation of xenobiotics.
  • the human isoenzymes of this cytochrome which have a substantial genetic polymorphism playing a role in the metabolization of the drugs, are: CYP2C9, CYP2C19, CYP2D6.
  • the optimization of a medical treatment according to the invention can comprise an optimization according to the genotype of the patient for the genes constituting the HLA system.
  • the information relating to the genotype of the patient can include information on the genotype of the patient for the genes of the HLA system.
  • Such an optimization is very advantageous as the genes of the HLA system are recognized as being the genetic markers for a person's susceptibility to diseases, allergies, infections, for his auto-immunity, etc.
  • other loci in the region of the HLA system influence certain of these factors. These loci are subject to new treatments, in particular immunobiotherapies.
  • the HLA system is involved in the response to vaccines, grafts and in undesirable reactions to numerous drugs.
  • the medical treatment can comprise at least one drug utilized in a cancer treatment.
  • the invention has the potential to offer individualized cancer treatment regimens.
  • TPMT thiopurine S- methyltransferase
  • 6-MP purine antimetabolite used in the treatment of leukaemia
  • Irinotecan (Camptosar®; Pfizer Pharmaceuticals) has potent antitumor activity against a wide range of tumors, and it is one of the most commonly prescribed chemotherapy agents. Diarrhea and myelosuppression are however, the dose-limiting toxicities of irinotecan and interfere with optimal utilization of this important drug. Studies of the clinical pharmacogenetics of irinotecan have been mainly focused on polymorphisms in UDP-glucuronosyltransferase IAl (UGTlAl), the enzyme for glucuronidation of SN-38 (Irinotecan active metabolite) to form the less toxic, inactive metabolite SN38G.
  • UDP-glucuronosyltransferase IAl UDP-glucuronosyltransferase IAl
  • Irinotecan active metabolite the enzyme for glucuronidation of SN-38 (Irinotecan active metabolite)
  • UGT1A1*28 The presence of seven TA repeats (referred to as UGT1A1*28), instead of the wild-type number of six, results in reduced UGTlAl expression and activity.
  • UGT1A1*28 has been shown to be associated with reduced glucuronidation of SN-38, increased exposure to SN-38, and increased clinical toxicity for patients treated with irinotecan. Clinical trials are ongoing or planned to address the impact of dose on irinotecan safety in patients with different UGT1A1*28 genotypes.
  • DPD Dihydropyrimidine dehydrogenase
  • 5-FU fluorodeoxyuridine monophosphate
  • FdUMP fluorodeoxyuridine monophosphate
  • TS thymidylate synthase
  • TS is an essential precursor of thymidine triphosphate, which is required for DNA synthesis and repair.
  • TS inhibition is an important target for 5-FU as well as other folate-based antimetabolites, and clinical resistance to these TS-targeted therapies has been linked to overexpression of TS in tumor.
  • TS expression levels in vivo appear to be regulated by the number of polymorphic tandem repeats in the TS enhancer region (TSER), where increases in TS expression and enzyme activity have been observed with increasing copies of the tandem repeats.
  • TSER TS enhancer region
  • TSER genotyping may be useful in selecting patients who are likely to respond to treatment with 5-FU or its analogues.
  • MDRl P- glycoprotein
  • Protein kinase mechanisms are used in signal transduction for the regulation of enzymes. Protein kinase polymorphisms appear important in the responsiveness to cancer treatment. EGFR (Epidermal Growth Factor Receptor), ERBB2, BRAF and KRAS2 genes are the most studied. Many studies show EGFR polymorphisms make the disease more responsive to treatment with tyrosine kinase inhibitors. For example, in a study with 118 surgically or gefitinib-treated lung cancer patients, some of gefitinib- responsive patients had L858R, whereas one gefitinib-resistant patient had G719S. In another study, an association between the EGFR signalling pathway and the response of cancer cells to ionizing radiation has been reported.
  • HER-I 497K and EGFR intron 1 (CA)(n) polymorphisms may be potential indicators of radiosensivity in patients with rectal cancer treated with chemoradiation.
  • genes such as the FLT3 receptor tyrosine kinase, FCG3RA IgG Fc receptor, methylenetetrahydrofolate reductase (MTHFR), N- acetyl transferases, DNA repair enzymes XPD and XRCCl, aldehyde dehydrogenase, glutathione S-tranferase (GSTPl) and multi-drug resistance associated protein (MRP2).
  • FLT3 receptor tyrosine kinase FCG3RA IgG Fc receptor
  • MTHFR methylenetetrahydrofolate reductase
  • N- acetyl transferases N- acetyl transferases
  • DNA repair enzymes XPD and XRCCl DNA repair enzymes XPD and XRCCl
  • aldehyde dehydrogenase aldehyde dehydrogenase
  • GSTPl glutathione S-tranferase
  • the method according to the invention advantageously comprises providing information on creating correlations of the data relating to interactions, in the form of a table in which the inputs represent the cytochrome P450 enzymes, the genotype of the patient in relation to these enzymes and names of the drugs.
  • the information on the lifestyle of the patient can comprise a medical history of the patient and information on the life habits of the patient namely, for example, whether he is a smoker or not.
  • This allows information collected in the patient's medical history to be advantageously incorporated in optimizing his medical treatment.
  • the method according to the invention allows certain reactions specific to the patient to be avoided, such as allergies, which would not be detected during the genetic testing or in the scientific literature. The optimization of the medical treatment will thus be more comprehensive.
  • the optimization can advantageously be completed by the information on the lifestyle of the patient including information relating to his nutrition.
  • information on the lifestyle of the patient including information relating to his nutrition.
  • the pharmacogenetic knowledge base defined by the method according to the invention can advantageously be an on-board base. It can just as easily be a base contained in a fixed location and accessible via a network connection. Moreover, it can advantageously be updated in line with new pharmacogenetic tests, new scientific data or any other information which may be involved in one way or another in the optimization of a medical treatment.
  • the method allows the pharmacodynamic interactions to be taken into account in the optimization of a medical treatment. These interactions refer to the antagonistic or synergetic actions between the plants or drugs. This occurs when a substance effects the assimilation or the clinical effectiveness of another substance when two substances, or more, are taken together.
  • a synergetic action takes place when two substances have identical properties, thus increasing or multiplying their actions.
  • An antagonist action signifies that it reduces or cancels the therapeutic effect.
  • the method according to the invention allows an optimization to be achieved so as not to have, in the same treatment, a drug or substance having the same target in order to avoid interactions.
  • the method according to the invention can advantageously include pharmacokinetic interactions. These interactions effect the capacity of the body to treat the absorption, distribution, the metabolism and the elimination of molecules, plants or drugs. The inclusion of these interactions in the method according to the invention allows an optimization of the medical treatment to be achieved in several respects:
  • the speed and/or the extent of the absorption of the different substances can be modified by several factors, such as for example: s
  • the change in intestinal pH modification of the absorption and degradation properties of the substance of interest.
  • Chelation formation of insoluble complexes which are not able to pass through the intestinal mucous membrane.
  • Modification of gastric emptying and of intestinal motility the presence or the absence of food can effect the absorption of drugs, and the administration of prokinetic agent can reduce the absorption of the molecules with poor solubility or the absorption occurs only in a limited section of the intestine.
  • the optimization in the medical treatment advantageously prevents a drug or another compound from significantly upsetting the distribution of the drugs prescribed.
  • the metabolic reactions i.e. from the biological conversion of a substance by one or more enzymatic systems take place in the liver.
  • the four main types of metabolic reactions are oxidation, reduction, hydrolysis (phase I reactions) and conjugation (phase II reactions).
  • the metabolites can be active, inactive or toxic.
  • the interactions which take place at the level of the metabolism are of two types: inhibition or induction of the cytochrome P450, and genetic polymorphism:
  • cytochrome P450 Inhibition / induction of cytochrome P450 enzymes Most of the oxidation reactions of the drugs (phase I reaction) are catabolized by a superfamily of mixed-function oxygenases which is known as the cytochrome P450.
  • the isoenzymes of cytochrome P450 (CYP) are mainly present in the liver, and they are the origin of a great number of significant pharmacokinetic drug interactions. Approximately 95% of all oxidations of drugs are catalyzed by the isoenzymes CYP1A2, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5.
  • a cytochrome P450-inhibiting drug erythromycin for example, administered at the same time as another drug metabolized by the same isoenzyme of cytochrome P450 (such as cyclosporine) will inhibit the metabolism of this drug (with inactive metabolite), and therefore produce an increase in the plasma concentrations, with a risk of toxicity.
  • a cytochrome P450-inducing drug, rifampicin for example, administered at the same time as another drug metabolized by the same isoenzyme of cytochrome P450 (such as an oral contraceptive) will speed up the metabolism of this drug (with active metabolite), and therefore produce a reduction in the plasma concentrations, with a risk of therapeutic failure.
  • the method in this case allows optimizing of the medical treatment in order not to have in the medical treatment inducers or inhibitors of the same isoenzyme metabolizing the drugs prescribed, or, in order to change the medical treatment to avoid induction or inhibition.
  • the subjects having the allele leading to the «normal» enzyme are called rapid metabolizers, while those having the allele leading to the «deficient» enzyme are called poor metabolizers.
  • this difference only has a clinical effect if the metabolic pathway effected is a quantitatively important pathway for the elimination of the drug in question and if the therapeutic range of this drug is small.
  • the clinical effect can be of two types in poor metabolizers: risk of toxicity for the drugs inactivated by the cytochrome in question; risk of therapeutic ineffectiveness for the drugs which require an activation by this same cytochrome in order to be active.
  • the method according to the invention advantageously allows optimizing of the medical treatment as a function of the phenotype for each isoenzyme of the cytochrome P450, in order to avoid any undesirable reactions. It also allows optimizing of the medical treatment as a function of the genotype of the patient relating to phase I and II biotransformation enzymes.
  • Drug interactions can alter the renal elimination of the drug.
  • the main mechanisms responsible are: s Glomerular filtration rate: when there is displacement of the protein bond, the increase in the free fraction of the drug which has been displaced is followed by an increase in the glomerular filtration rate and therefore the excretion of this drug.
  • s Tubular secretion when two drugs using the same tubular secretion transporter are co-administered, there is competition between these two drugs, and therefore reduction in the renal elimination of the «losing» drug.
  • probenecid administered at the same time as penicillin prevents the tubular secretion of penicillin, which leads to an increase in the plasma concentrations of the antibiotic.
  • a change in urinary pH will alter the proportion of ionized/non-ionized molecules present at the level of the renal tubule. However, only the non-ionized molecules are reabsorbed passively. Consequently the renal clearance of the weak bases is increased by acidifying the urine, while that of the weak acids is increased by alkalinising the urine.
  • the significance of this type of interaction is moderate or even weak, because very few drugs are excreted in an unchanged form in urine, most of them are converted beforehand into inactive metabolites by the liver.
  • the optimization of the medical treatment according to the method allows significant disturbance in the excretion of drugs to be avoided.
  • the data on the genotype of the patient can advantageously include information on transporters involved in a genetic metabolization of drugs.
  • This information in particular relates to the genotype of the patient with regard to these transporters.
  • the method according to the invention can include interactions relating to transporters involved in the metabolization of drugs.
  • P-glycoprotein constitutes the most studied drug transporter.
  • This protein being strongly expressed in the organism and playing an important role in the intestinal absorption of the drugs and/or their distribution in the different cellular compartments, it can thus alter their plasma or intracellular concentrations and influence the response to treatment.
  • wild homozygotes normal expression
  • deficient homozygotes weak expression
  • heterozygotes reduced expression
  • the drugs which can induce or inhibit this transport protein must be taken into consideration, because the induction of the protein activity can compensate for being a deficient homozygote, can cause the activity of P-gp to be reduced in a wild homozygote and can make it normal in a heterozygote.
  • the inhibition of the protein activity can render this activity nil or very reduced in a deficient homozygote or a heterozygote, and can also reduce this activity in a wild homozygote.
  • the method according to the invention can include an interaction relating to receptors involved in a metabolization of drugs.
  • the data on the genotype of the patient can include information on these receptors and on the genotype of the patient in relation to these receptors.
  • An optimization of the medical treatment as a function of the genotype of the receptors is possible thanks to the method according to the invention.
  • the metabolized drug once it has reached the receptor, must bind with the latter, in order for a signalling pathway to be started.
  • the polymorphism of the receptors is therefore also very important for the response to the treatment. Since, according to the genetic variant the receptor can change its conformation with respect to the wild phenotype, thus the ligand (metabolite) binds with the receptor with an affinity which is not as good or no longer binds at all: there is then no cell transmission and therefore no therapeutic effect.
  • the receptor can also be non-functional even if there is ligand/receptor interaction, i.e. the receptor is incapable of transmitting the information: there is no therapeutic effect.
  • Some drugs can induce or inhibit receptor activity, just like the transporters.
  • the scientific literature particularly emphasizes inhibition, i.e. the ligand (antagonist) blocks the binding site of the second ligand, or the ligand (antagonist) binds and produces a conformational change which leads to a loss of binding of the second ligand at its site.
  • receptors and transporters dealt with by the method according to the invention are serotonin receptors, serotonin, tryptophan, hydroxylase, G-protein beta3, apolipoprotein and E type 4 (ApOE-e4) transporters.
  • the method according to the invention comprises in particular the optimization of a medical treatment, and in particular of anti-cancer treatments as a function of the genotype of the genes of the protein kinases recognized as playing an essential role in cancer.
  • computing equipment used in the optimization of a medical treatment, comprising: - means for acquiring data relating to the medical treatment envisaged for a patient, - means for acquiring data relating to the genotype of the patient,
  • - software means arranged in order to identify, from said acquired data and from a pharmacogenetic knowledge base containing information on gene-drug and drug-drug interactions, potential drug- drug and/or gene-drug interactions in the case of said treatment, and
  • the computing equipment can advantageously be portable equipment. It can be a laptop computer using the method according to the invention, in order that it can be more easily transported by the doctor.
  • a laptop computer has the characteristic of being equipment which is easy to use and which is commonplace.
  • the acquisition means are means which are integrated in this equipment, such as a keyboard, a mouse or a touch screen equipped or not equipped with a pen. These acquisition means are in no way limitative.
  • the software means can be on-board or means downloaded for each use from a site accessible via a network of the internet type. They can, for example, comprise an inference engine.
  • the means for providing information can include means for displaying or viewing information. These means can advantageously be on-boarc! or otherwise.
  • an information system for producing data for optimizing a medical treatment, comprising: means for storing data on the genotype of a patient,
  • the means for storage of data on the genotype of the patient are advantageously organized in the form of portable means such as a USB (Universal Serial Bus) memory stick, a floppy disk, an optical medium of the compact disk (CD) type, a zip disk, an electronic chip inserted or not into the patient's skin, or a card equipped with an electronic chip.
  • portable means such as a USB (Universal Serial Bus) memory stick, a floppy disk, an optical medium of the compact disk (CD) type, a zip disk, an electronic chip inserted or not into the patient's skin, or a card equipped with an electronic chip.
  • Figure 1 shows an example of a block diagram of the method of generating optimizing data according to the invention
  • Figure 2 describes an example of a global process of the optimization system, integrating the evolutionary multicriteria optimization
  • Figure 3 describes, in the context of an example of optimization of medical treatment, the level of fluvoxamine in the blood;
  • Figure 4 describes an example of a patient's phenotype for each of the cytochrome P450 enzyme
  • Figure 5 describes a classification of phenotypes as a function of genotypes, as used in the method according to the invention
  • Figure 6 describes an example of a correlation of the data on the genotype of the patient, his phenotype, the cytochrome P450 enzymes and the drugs, as used in the method according to the invention
  • Figure 7 describes an example of correlation of the hormones and of the cytochrome P450 enzymes, as used in the method according to the invention.
  • Figure 8 describes an example of correlation of plants and of cytochrome P450 enzymes, as used in the method according to the invention.
  • FIG 8 describes an example of correlation of plants and of cytochrome P450 enzymes, as used in the method according to the invention.
  • Fluvoxamine is a strong clozapine N-demethylation inhibitor, which corresponds to the main metabolization of clozapine. This means that by prescribing 150 mg/day of fluvoxamine, the doctor would greatly reduce the metabolic capacity of the patient for clozapine.
  • the system according to the invention will propose a more suitable treatment, if one exists, than that presently administered.
  • Several means can be used to optimize the treatment. The first consists of changing the dosages of one or more drugs constituting the treatment. The second consists of changing one or more drugs among those used by the patient.
  • the optimization of the treatment can be carried out in several stages:
  • the current treatment and the patient's information are sent to the DEM (dosage evaluation module) and to the ATM (alternative treatment module) at the same time.
  • the patient's information includes his genotype, his clinical history, and the different information relevant for the DEM and the ATM.
  • the DEM communicates with the DGSB (drug-gene and statistics knowledge base, or pharmacogenetic knowledge base) in order to obtain the pharmacogenetic data relating to the drugs taken by the patient.
  • the latter are transformed into a set of mathematical variables and functions (objectives), which can be understood by the OS (optimization system) and which is then sent to the latter.
  • the OS will then try to optimize as much as possible the dosages of the different drugs by finding the best compromise.
  • the result is then sent back to the DEM accompanied by a value GFV DEM (global fitness value). This value is calculated by comparing the optimized result and the ideal result (which is impossible in reality considering all of the objectives to be satisfied).
  • the result is a group of drugs identical to that of the treatment presently prescribed but with different dosages.
  • the DEM can then verify the integrity of the result and carry out various post-optimization checks.
  • the ATM alternative treatment module
  • the DGSB communicates with the DGSB, to obtain and transform the pharmacogenetic data in order to send it to the OS in a format suited to the latter.
  • the result in this case will be a set of numerical values corresponding to the set of values of the optimal input variables.
  • This result does not describe a new combination of drugs but the expression of a more suitable treatment as a function of the input variables of the OS.
  • the DM (decision maker) serves, among other things, to choose the treatment corresponding to such numerical values.
  • the ATM and the DEM after having carried out all the necessary checks, each send back their results as well as the respective GFVs to the DM. Another piece of information is sent: the signature.
  • the DM as a function of the GFVs will choose the result by comparing the various respective GFVs. The result with the greatest GFV defines the most valid result. If the signature of the result is that of the ATM, the DM will choose the combination of drug which best corresponds to the set of numerical variables of the result of the OS. This will thus result in a new treatment proposal.
  • the function will be, as is shown in Figure 3, the clozapine blood level as a function of the prescribed dose and of the fluvoxamine blood level.
  • the clozapine blood level is that observed during a parallel treatment with fluvoxamine.
  • the dosage of fluvoxamine is sought to be maintained constant.
  • the straight line which is of interest therefore, is that for which the blood level is 5 ⁇ M.
  • the 150 mg/day of luvox produces this blood level of fluvoxamine.
  • the present example of medical treatment is a specific case and is in no way limitative. If necessary, other factors could simultaneously be considered in the optimization, in order to obtain the best compromise while respecting several objectives.
  • the genotype of the patient as shown in Figures 4 and 5, could have been taken into consideration in the optimization, in order to obtain an even more personalized dosage.
  • An evaluation of the drugs category by category as shown by Figure 6, as well as an evaluation of the interactions linked to the transporters and to the receptors could also be envisaged, if this proves to be necessary in the optimization. These interactions are detected thanks to the scientific information contained in the pharmacogenetic knowledge base.
  • all the inhibiting or reducing hormones of a cytochrome P450 enzyme in particular could be considered, if this were necessary. This consideration can be carried out through an evaluation of the hormones, as shown by Figure 7.
  • the method according to the invention also allows inclusion of the interactions linked to plants. If necessary, these interactions can be considered by identifying the effects of the plants on the metabolism of the patient, as shown by Figure 8.
  • the method, the device and the system according to the invention are not limited to the detailed example below and can be applied to any treatment, medical or otherwise, applied to living organisms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Social Psychology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention permet d'optimiser un traitement médical administré à un patient et propose un choix de traitements médicaux de deuxième intention, en accord avec le génotype du patient, des interactions potentielles entre les médicaments, des gènes impliqués dans le processus médical et des informations et diagnostics concernant le patient. L'invention fait intervenir un procédé de production de données visant à optimiser un traitement médical, mis en oeuvre dans un équipement de calcul, qui consiste à: acquérir des données relatives au traitement médical envisagé pour le patient; acquérir des données relatives au génotype du patient; acquérir des données relatives au mode de vie du patient; identification, à partir des données acquises et d'une base de connaissances contenant des informations pharmacogénétiques, des interactions pharmacogénétiques potentielles dans le cas d'un tel traitement; identification, à partir des interactions potentielles identifiées, d'au moins une possibilité d'optimisation de ce traitement, et mise à disposition des données d'optimisation de ce traitement.
PCT/EP2006/006094 2005-06-24 2006-06-23 Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme WO2006136449A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06754539A EP1946231A1 (fr) 2005-06-24 2006-06-23 Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0506484A FR2887663A1 (fr) 2005-06-24 2005-06-24 Procede et systeme d'information pour generer des donnees d'optimisation d'un traitement medical, et equipement mis en oeuvre dans ce systeme
FR0506484 2005-06-24
US11/194,587 2005-08-02
US11/194,587 US20060289019A1 (en) 2005-06-24 2005-08-02 Information method and system for generating data for optimizing a medical treatment, and equipment used in this system

Publications (1)

Publication Number Publication Date
WO2006136449A1 true WO2006136449A1 (fr) 2006-12-28

Family

ID=36999262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006094 WO2006136449A1 (fr) 2005-06-24 2006-06-23 Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme

Country Status (2)

Country Link
EP (1) EP1946231A1 (fr)
WO (1) WO2006136449A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031073A3 (fr) * 2007-09-04 2009-08-20 Koninkl Philips Electronics Nv Appareil et procédé de planification de traitements multiples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153819A1 (en) * 1997-03-13 2003-08-14 Iliff Edwin C. Disease management system and method including correlation assessment
US20040030503A1 (en) * 1999-11-29 2004-02-12 Scott Arouh Neural -network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including susceptibility to disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153819A1 (en) * 1997-03-13 2003-08-14 Iliff Edwin C. Disease management system and method including correlation assessment
US20040030503A1 (en) * 1999-11-29 2004-02-12 Scott Arouh Neural -network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including susceptibility to disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROCKMOELLER J ET AL: "PHARMACOGENETIC DIAGNOSTICS OF CYTOCHROME P450 POLYMORPHISMS IN CLINICAL DRUG DEVELOPMENT AND IN DRUG TREATMENT", PHARMACOGENOMICS, ASHLEY PUBLICATIONS, GB, vol. 1, no. 2, May 2000 (2000-05-01), pages 125 - 151, XP008020668, ISSN: 1462-2416 *
EVANS W E ET AL: "Pharmacogenomics - Drug disposition, drug targets, and side effects", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 348, no. 6, 6 February 2003 (2003-02-06), pages 538 - 549, XP002339735, ISSN: 0028-4793 *
TALBOT J, WALLER P: "Stephens' Detection of New Adverse Drug Reactions (Fifth Edition)", December 2004, JOHN WILEY & SONS, LTD, ISBN: 0-470-84552-X, XP002401103 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031073A3 (fr) * 2007-09-04 2009-08-20 Koninkl Philips Electronics Nv Appareil et procédé de planification de traitements multiples
US8660800B2 (en) 2007-09-04 2014-02-25 Koninklijke Philips N.V. Multi-treatment planning apparatus and method
US10521563B2 (en) 2007-09-04 2019-12-31 Koninklijke Philips N.V. Multi-treatment planning apparatus and method

Also Published As

Publication number Publication date
EP1946231A1 (fr) 2008-07-23

Similar Documents

Publication Publication Date Title
US20060289019A1 (en) Information method and system for generating data for optimizing a medical treatment, and equipment used in this system
Boige et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial
Braun et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial
Bowden et al. A genome scan for diabetic nephropathy in African Americans
Maher et al. The AVPR1A gene and substance use disorders: association, replication, and functional evidence
Ansari et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
Ulrich et al. Cancer pharmacogenetics: polymorphisms, pathways and beyond
Evans et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
Watters et al. Cancer pharmacogenomics: current and future applications
Davies Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?
de Klerk et al. Altered blood gene expression in the obesity-related type 2 diabetes cluster may be causally involved in lipid metabolism: a Mendelian randomisation study
Li et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
Lešnjaković et al. DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?
Hooshmand et al. Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study
Zhang et al. Gender-specific differences in expression in human lymphoblastoid cell lines
Mostafa et al. Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia
Daniel et al. Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity
EP1946231A1 (fr) Procede et systeme de production de donnees en vue de l'optimisation d'un traitement medical, et equipement utilise dans ce systeme
Kager et al. Pharmacogenomics of acute lymphoblastic leukemia
Dollery Beyond genomics
Awdishu et al. Role of pharmacogenomics in kidney disease and injury
Karlsson et al. Epigenome-wide association study of level and change in cognitive abilities from midlife through late life
Bridges Jr Personalized Medicine in Rheumatoid Arthritis.
Zhang et al. A Three‐mRNA Signature Associated with Pyrimidine Metabolism for Prognosis of BRCA
CN100453650C (zh) 预测免疫抑制治疗期间胆固醇升高的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006754539

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006754539

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载